UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 120

Sortiert nach

The effects of itraconazole on inflammatory bowel disease activity in patients treated for histoplasmosis

Alimentary pharmacology & therapeutics, 2010-11, Vol.32 (9), p.1207-1209

2010

Link zum Volltext

Verfügbarkeit prüfen

Letter: the definition of budesonide dependence in microscopic colitis—authors’ reply

Alimentary pharmacology & therapeutics, 2017-09, Vol.46 (6), p.636-636

2017

Link zum Volltext

Verfügbarkeit prüfen

Evolving Molecular Targets in the Treatment of Nonmalignant Gastrointestinal Diseases

Clinical pharmacology and therapeutics, 2012-09, Vol.92 (3), p.306-320

2012

Link zum Volltext

Verfügbarkeit prüfen

Systematic review: colitis associated with anti‐CTLA‐4 therapy

Alimentary pharmacology & therapeutics, 2015-08, Vol.42 (4), p.406-417

2015

Link zum Volltext

Verfügbarkeit prüfen

Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2016-04, Vol.43 (8), p.863-883

2016

Link zum Volltext

Verfügbarkeit prüfen

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

The American journal of gastroenterology, 2015-09, Vol.110 (9), p.1324-1338

2015

Link zum Volltext

Verfügbarkeit prüfen

Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2018-07, Vol.48 (2), p.190-195

2018

Link zum Volltext

Verfügbarkeit prüfen

Systematic review with meta‐analysis: faecal diversion for management of perianal Crohn's disease

Alimentary pharmacology & therapeutics, 2015-10, Vol.42 (7), p.783-792

2015

Link zum Volltext

Verfügbarkeit prüfen

Meta‐analysis: serological markers and the risk of acute and chronic pouchitis

Alimentary pharmacology & therapeutics, 2013-05, Vol.37 (9), p.867-875

2013

Link zum Volltext

Verfügbarkeit prüfen

Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis

Alimentary pharmacology & therapeutics, 2004-01, Vol.19 (2), p.179

2004

Link zum Volltext

Verfügbarkeit prüfen

The natural history of perianal Crohn's disease

Digestive and liver disease, 2007-10, Vol.39 (10), p.963-969

2007

Link zum Volltext

Verfügbarkeit prüfen

Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy

Drug design, development and therapy, 2016-01, Vol.10, p.3685-3698

2016

Link zum Volltext

Verfügbarkeit prüfen

Editorial: biologic therapies for primary sclerosing cholangitis—more disappointment than promise? Authors’ reply

Alimentary pharmacology & therapeutics, 2018-09, Vol.48 (5), p.578-579

2018

Link zum Volltext

Verfügbarkeit prüfen

P734 Super-responders in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab maintenance therapy: A post hoc analysis of the LIBERTY-CD study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1375-i1376

2024

Link zum Volltext

Verfügbarkeit prüfen

P540 Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: An analysis of the phase 2 OASIS and phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1062-i1064

2024

Link zum Volltext

Verfügbarkeit prüfen

P786 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn’s disease

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i919-i920

2023

Link zum Volltext

Verfügbarkeit prüfen

P439 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn’s disease

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i568-i569

2023

Link zum Volltext

Verfügbarkeit prüfen

OP10 Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn’s Disease: results from the U-ENDURE long-term extension

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i17-i18

2024

Link zum Volltext

Verfügbarkeit prüfen

P862 Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 2b/3 trials

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1596-i1597

2024

Link zum Volltext

Verfügbarkeit prüfen

P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i574-i576

2023

Link zum Volltext

Verfügbarkeit prüfen

P854 Race and ethnicity in ulcerative colitis clinical trial enrolment: a post hoc analysis of patient demographics and clinical characteristics from GEMINI 1, VARSITY, and VISIBLE 1

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i977-i979

2023

Link zum Volltext

Verfügbarkeit prüfen

P705 Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programme

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1330-i1332

2024

Link zum Volltext

Verfügbarkeit prüfen

P678 Long-term efficacy, safety and health-related quality of life in patients who achieved comprehensive disease control with filgotinib in SELECTION: analysis of ~3 years in SELECTIONLTE

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1288-i1289

2024

Link zum Volltext

Verfügbarkeit prüfen

Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma – authors' reply

Alimentary pharmacology & therapeutics, 2016-01, Vol.43 (1), p.176-176

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 120

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(117)
Mit Volltextzugriff
(102)

Publikationsform

Artikel
(120)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(79)
Science & Technology
(79)
Gastroenterology & Hepatology
(70)
Humans
(67)
Crohn's Disease
(22)
Gastroenterology
(18)
Inflammatory Bowel Disease
(18)
Pharmacology & Pharmacy
(15)
Biological And Medical Sciences
(13)
Medical Sciences
(13)
Ulcerative Colitis
(12)
Treatment Outcome
(11)
Adult
(9)
Crohn Disease - Drug Therapy
(9)
Gastroenterology. Liver. Pancreas. Abdomen
(9)
Hepatology
(9)
Crohn Disease - Epidemiology
(8)
Inflammatory Bowel Diseases
(8)
Risk Factors
(8)
Female
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus

The effects of itraconazole on inflammatory bowel disease activity in patients treated for histoplasmosis

Letter: the definition of budesonide dependence in microscopic colitis—authors’ reply

Evolving Molecular Targets in the Treatment of Nonmalignant Gastrointestinal Diseases

Systematic review: colitis associated with anti‐CTLA‐4 therapy

Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease

Systematic review with meta‐analysis: faecal diversion for management of perianal Crohn's disease

Meta‐analysis: serological markers and the risk of acute and chronic pouchitis

Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis

The natural history of perianal Crohn's disease

Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy

Editorial: biologic therapies for primary sclerosing cholangitis—more disappointment than promise? Authors’ reply

P734 Super-responders in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab maintenance therapy: A post hoc analysis of the LIBERTY-CD study

P540 Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: An analysis of the phase 2 OASIS and phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials

P786 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn’s disease

P439 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn’s disease

OP10 Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn’s Disease: results from the U-ENDURE long-term extension

P862 Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 2b/3 trials

P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis

P854 Race and ethnicity in ulcerative colitis clinical trial enrolment: a post hoc analysis of patient demographics and clinical characteristics from GEMINI 1, VARSITY, and VISIBLE 1

P705 Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programme

P678 Long-term efficacy, safety and health-related quality of life in patients who achieved comprehensive disease control with filgotinib in SELECTION: analysis of ~3 years in SELECTIONLTE

Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma – authors' reply

Aktive Filter

Suchergebnisse filtern